Used for the treatment of depression that does not respond to standard antidepressant medications, the anesthesia drug ketamine—and the related drug esketamine, recently approved for depression treatment—has no important adverse effects on memory, attention, or other cognitive processes, concludes a systematic review of medical research in the September/October issue of Harvard Review of Psychiatry.